Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Phase II trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate CancerClin. Cancer Res 2022 Oct 18;[EPub Ahead of Print], UN Vaishampayan, A Thakur, W Chen, A Deol, M Patel, K Dobson, B Dickow, D Schalk, A Schienschang, S Whitaker, A Polend, JA Fontana, EI Heath, LG Lum
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.